Navigation Links
Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
Date:6/20/2013

SAN DIEGO, June 20, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) a biopharmaceutical company focused on the treatment of obesity, today announced the schedule of its upcoming Contrave® (naltrexone sustained release (SR) /bupropion SR) clinical data presentations taking place at the American Diabetes Association (ADA) 73rd Scientific Sessions, June 21-25, 2013.

ADA: McCormick Place Convention Center (West Building), Chicago, ILAbstract# 1056-P – "Combination Naltrexone/Bupropion Therapy Resulted in Clinically Meaningful Improvements in Weight and Quality of Life - Integrated Analysis of Four Phase 3 Trials"
Lead Author: Ronette L. Kolotkin

Abstract# 1130-P – "An Integrated Analysis of Weight Loss with Combination Naltrexone/Bupropion Therapy by BMI (Obesity) Classification"
Lead Author: Caroline M. Apovian

Abstract# 1149-P – "Early Improvement in Control of Eating Is Associated with Long-term Weight Loss - Integrated Analysis of Four Phase 3 Trials of Combination Naltrexone/Bupropion Treatment"
Lead Author: Ken Fujioka

All abstracts will be presented at General Poster Session 2, on Sunday, June 23, from 12:00 PM - 2:00 PM, in Hall F1 – Posters.

Abstract #1056-P will also be showcased in a Guided Audio Poster Tour at the Innovative Oral Agents–Innovative Discoveries session on Monday, June 24, from 1:00 PM - 2:00 PM.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

BrewLife(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
2. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
3. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
4. Orexigen Therapeutics to Host Full Year and Fourth Quarter 2012 Financial Results Conference Call and Webcast
5. Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the Cowen & Co. Annual Health Care Conference
6. Orexigen Therapeutics to Present at Upcoming Investor Conferences
7. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
8. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
9. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
10. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
11. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2020)... FREEDOM, Pa. (PRWEB) , ... May 16, 2020 , ... ... has developed a low-cost proning cushion to help patients lay face down for extended ... providing proning devices for over 15 years to PTs and Pain Management professionals. We ...
(Date:5/14/2020)... ... May 14, 2020 , ... A new study from the National Alliance ... United States increased by 9.5 million from 2015 to 2020 and now encompasses more ... family caregivers are in worse health compared to five years ago. As the demand ...
(Date:5/14/2020)... ... ... Clear Labs , providers of the only automated and intelligent diagnostic ... by Redmile Group, as well as existing investors including Wing VC, Menlo Ventures, Tyson ... raised $62M. , In addition to supporting ongoing commercialization of the company’s food ...
Breaking Medicine Technology:
(Date:5/16/2020)... , ... May 15, 2020 , ... For patients who have gone to see ... that the office has always had in place. After being allowed to re-open during the ... that patients and staff are as safe and comfortable as possible while going through their ...
(Date:5/15/2020)... ... May 15, 2020 , ... Collagen has taken the ... natural channel alone in 2019, according to a 2020 Nutritional Outlook ‘Ingredients to Watch’ ... further and further away from the high molecular weight, low-impact products of the past ...
(Date:5/15/2020)... PHOENIX (PRWEB) , ... May 15, 2020 , ... How ... question remains unanswered. Thousands of private practice offices are not set up to see ... lack of patient and disease history are challenging to overcome. Doctors and patients need ...
(Date:5/14/2020)... ... May 13, 2020 , ... The Long Island-based ... Developmental Disabilities. , The vision of the Center for Developmental Disabilities is to ... values are embraced: Everyone is treated with dignity and respect. Individual strengths and ...
(Date:5/11/2020)... ... May 11, 2020 , ... PathologyWatch announced today a $5M ... Capital with additional funding by individual investors. PathologyWatch is emerging as the ... process while reducing costs to clinics and enhancing patient care. , ...
Breaking Medicine News(10 mins):